A Phase 3 interventional study of Galcanezumab and Placebo in Migraine, sponsored by Eli Lilly and Company. Completed at 69 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 463 is above the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Galcanezumab administered subcutaneously (SC).
Drug: Galcanezumab
Placebo administered SC.
Drug: Placebo
Administered SC.
Also known as: LY2951742
Administered SC.
Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days
Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 3 from mixed model repeated measures (MMRM) model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
Time frame: Baseline, Month 1 through Month 3
Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days in Participants With Episodic Migraine
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 3 from MMRM model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
Time frame: Baseline, Month 1 through Month 3
Percentage of Participants With ≥50% Reduction From Baseline in Monthly Migraine Headache Days
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 50% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
Time frame: Baseline, Month 1 through Month 3
Percentage of Participants With Episodic Migraine With ≥50% Reduction From Baseline in Monthly Migraine Headache Days
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 50% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
Time frame: Baseline, Month 1 through Month 3
Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)
MSQ v2.1 is a health status instrument, with a 4-week recall period, developed to address physical and emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family \& friends, leisure time, productivity, concentration, energy, tiredness \& feelings. It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);\&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6),\& are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status \& a positive change in scores reflecting functional improvement.
Time frame: Baseline, Month 3
Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1) in Participants With Episodic Migraine
MSQ v2.1 is a health status instrument, with a 4-week recall period, developed to address physical and emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family \& friends, leisure time, productivity, concentration, energy, tiredness \& feelings. It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);\&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6),\& are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status \& a positive change in scores reflecting functional improvement.
Time frame: Baseline, Month 3
Percentage of Participants With Episodic Migraine With ≥75% Reduction From Baseline in Monthly Migraine Headache Days
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 75% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
Time frame: Baseline, Month 1 through Month 3
Percentage of Participants With Episodic Migraine With 100% Reduction From Baseline in Monthly Migraine Headache Days
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with 100% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
Time frame: Baseline, Month 1 through Month 3
Percentage of Participants With ≥75% Reduction From Baseline in Monthly Migraine Headache Days
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 75% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
Time frame: Baseline, Month 1 through Month 3
Percentage of Participants With 100% Reduction From Baseline in Monthly Migraine Headache Days
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with 100% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
Time frame: Baseline, Month 1 through Month 3
Overall Mean Change From Baseline in the Number of Monthly Days With Acute Headache Medication Use
Overall mean is derived from the average of months 1 to 3 from Mixed model repeated measures (MMRM) model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
Time frame: Baseline, Month 1 through Month 3
Overall Mean Change From Baseline in the Number of Monthly Headache Days
Headache Day: A calendar day on which any type of headache occurred (including migraine, probable migraine, and non-migraine headache). Overall mean is derived from the average of months 1 to 3 from MMRM model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
Time frame: Baseline, Month 1 through Month 3
Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score
The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missed or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. LS mean was calculated using analysis of covariance (ANCOVA) with last observation carried forward (LOCF), with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
Time frame: Baseline, Month 3
Mean Change From Baseline in the 4-item Migraine Interictal Burden Scale (MIBS-4)
MIBS-4 is a self-administered scale that measures the burden related to headache in the time between attacks. The instrument consists of 4 items that address disruption at work and school, diminished family and social life, difficulty planning, and emotional difficulty. The questionnaire specifically asks about the effect of the disease over the past 4 weeks on days without a headache attack. Response options include: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each responses associated numerical score are summed across all 4 items resulting in a total score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none, 1-2 mild, 3-4 moderate, and \>5 severe. LS mean was calculated using MMRM model with fixed effects of treatment, pooled country, baseline migraine frequency category, month, treatment by month as fixed effects.
Time frame: Baseline, Month 3
Mean Change From Baseline in the Work Productivity and Activity Impairment Questionnaire (WPAI)
The WPAI Questionnaire is a patient-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores are calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores are calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes. LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
Time frame: Baseline, Month 3
Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S)
The PGI-S is a patient-rated instrument that measures illness severity. For this study, the patient was instructed as follows: "Considering migraine as a chronic condition, how would you rate your level of illness?" The PGI-S includes a range of possible responses, from 1 ("normal, not at all ill") to 7 ("extremely ill"). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
Time frame: Baseline, Month 3
Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - Health State Index (US)
EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state. LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
Time frame: Baseline, Month 3
Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - Health State Index (UK)
EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the UK algorithm (-0.594 to 1). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
Time frame: Baseline, Month 3
Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - VAS Score
EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. . The second part is assessed using a visual analog scale (VAS) on which the patient rates their perceived health state, ranging from 0 (the worst health you can imagine) to 100 (the best health you can imagine). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
Time frame: Baseline, Month 3
| Milestone | Placebo/Galcanezumab 120mg | Galcanezumab 120mg |
|---|---|---|
| Started | 230 | 233 |
| Received at least one dose of study drug | 230 | 232 |
| Completed | 226 | 225 |
| Not completed | 4 | 8 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Protocol violation | 1 | 4 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Screen failure | 0 | 1 |
| Milestone | Placebo/Galcanezumab 120mg | Galcanezumab 120mg |
|---|---|---|
| Started | 225 | 224 |
| Completed | 215 | 217 |
| Not completed | 10 | 7 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Lack of efficacy | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 3 from mixed model repeated measures (MMRM) model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
| Days | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days | -1.02 ± 0.32 | -4.14 ± 0.32 |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 3 from MMRM model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
| Days | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days in Participants With Episodic Migraine | -0.31 ± 0.34 | -2.88 ± 0.34 |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 50% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
| Percentage of Participants | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Percentage of Participants With ≥50% Reduction From Baseline in Monthly Migraine Headache Days | 13.3 (10.2 to 17.3) | 37.7 (32.9 to 42.8) |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 50% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
| Percentage of Participants | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Percentage of Participants With Episodic Migraine With ≥50% Reduction From Baseline in Monthly Migraine Headache Days | 17.1 (12.7 to 22.7) | 41.8 (35.7 to 48.1) |
MSQ v2.1 is a health status instrument, with a 4-week recall period, developed to address physical and emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family \& friends, leisure time, productivity, concentration, energy, tiredness \& feelings. It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);\&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6),\& are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status \& a positive change in scores reflecting functional improvement.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1) | 10.68 ± 1.34 | 23.21 ± 1.35 |
MSQ v2.1 is a health status instrument, with a 4-week recall period, developed to address physical and emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family \& friends, leisure time, productivity, concentration, energy, tiredness \& feelings. It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);\&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6),\& are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status \& a positive change in scores reflecting functional improvement.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1) in Participants With Episodic Migraine | 11.88 ± 1.80 | 23.39 ± 1.79 |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 75% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
| Percentage of Participants | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Percentage of Participants With Episodic Migraine With ≥75% Reduction From Baseline in Monthly Migraine Headache Days | 3.7 (1.6 to 8.2) | 18.4 (13.9 to 23.9) |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with 100% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
| Percentage of Participants | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Percentage of Participants With Episodic Migraine With 100% Reduction From Baseline in Monthly Migraine Headache Days | 0.00 (0.00 to 0.00) | 7.7 (4.7 to 12.3) |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with at least a 75% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
| Percentage of Participants | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Percentage of Participants With ≥75% Reduction From Baseline in Monthly Migraine Headache Days | 3.3 (1.7 to 6.3) | 14.5 (10.9 to 19.0) |
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of patients with 100% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.
| Percentage of Participants | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Percentage of Participants With 100% Reduction From Baseline in Monthly Migraine Headache Days | 0.000 (0.000 to 0.000) | 4.9 (2.8 to 8.6) |
Overall mean is derived from the average of months 1 to 3 from Mixed model repeated measures (MMRM) model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
| Days | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Overall Mean Change From Baseline in the Number of Monthly Days With Acute Headache Medication Use | -0.80 ± 0.31 | -4.19 ± 0.32 |
Headache Day: A calendar day on which any type of headache occurred (including migraine, probable migraine, and non-migraine headache). Overall mean is derived from the average of months 1 to 3 from MMRM model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.
| Days | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Overall Mean Change From Baseline in the Number of Monthly Headache Days | -1.05 ± 0.36 | -4.18 ± 0.35 |
The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missed or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. LS mean was calculated using analysis of covariance (ANCOVA) with last observation carried forward (LOCF), with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score | -3.295 ± 3.2834 | -21.097 ± 3.3164 |
MIBS-4 is a self-administered scale that measures the burden related to headache in the time between attacks. The instrument consists of 4 items that address disruption at work and school, diminished family and social life, difficulty planning, and emotional difficulty. The questionnaire specifically asks about the effect of the disease over the past 4 weeks on days without a headache attack. Response options include: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each responses associated numerical score are summed across all 4 items resulting in a total score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none, 1-2 mild, 3-4 moderate, and \>5 severe. LS mean was calculated using MMRM model with fixed effects of treatment, pooled country, baseline migraine frequency category, month, treatment by month as fixed effects.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the 4-item Migraine Interictal Burden Scale (MIBS-4) | -0.78 ± 0.21 | -1.83 ± 0.21 |
The WPAI Questionnaire is a patient-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores are calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores are calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes. LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Activity Impairment | -8.644 ± 1.9195 | -20.713 ± 1.9537 |
| Absenteeism | -2.900 ± 1.2436 | -4.224 ± 1.2929 |
| Presenteeism | -2.564 ± 2.3222 | -12.504 ± 2.3705 |
| Work Impairment | -3.457 ± 2.4098 | -14.307 ± 2.5148 |
The PGI-S is a patient-rated instrument that measures illness severity. For this study, the patient was instructed as follows: "Considering migraine as a chronic condition, how would you rate your level of illness?" The PGI-S includes a range of possible responses, from 1 ("normal, not at all ill") to 7 ("extremely ill"). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) | -0.283 ± 0.0863 | -0.664 ± 0.0873 |
EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state. LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - Health State Index (US) | -0.002 ± 0.0079 | 0.013 ± 0.0080 |
EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the UK algorithm (-0.594 to 1). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
| score on a scale | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - Health State Index (UK) | -0.001 ± 0.0109 | 0.017 ± 0.0110 |
EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. . The second part is assessed using a visual analog scale (VAS) on which the patient rates their perceived health state, ranging from 0 (the worst health you can imagine) to 100 (the best health you can imagine). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.
| mm | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase |
|---|---|---|
| Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - VAS Score | -0.086 ± 1.2916 | 3.376 ± 1.3080 |
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | 0/230 (0%) | 2/230 (0.9%) | 31/230 (13.5%) |
| Galcanezumab 120mg - Double-Blind Treatment Phase | 0/232 (0%) | 2/232 (0.9%) | 21/232 (9.1%) |
| Placebo/Galcanezumab 120mg - Open-Label Treatment Phase | 0/225 (0%) | 6/225 (2.7%) | 19/225 (8.4%) |
| Galcanezumab 120mg/Galcanezumab 120mg - Open-Label Treatment | 0/224 (0%) | 3/224 (1.3%) | 13/224 (5.8%) |
| Event | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase | Placebo/Galcanezumab 120mg - Open-Label Treatment Phase | Galcanezumab 120mg/Galcanezumab 120mg - Open-Label Treatment |
|---|---|---|---|---|
| Ovarian cyst rupturedReproductive system and breast disorders | 0/202 | 0/195 | 0/197 | 1/187 |
| AstheniaGeneral disorders | 0/230 | 0/232 | 0/225 | 1/224 |
| PneumoniaInfections and infestations | 0/230 | 0/232 | 0/225 | 1/224 |
| Inguinal herniaGastrointestinal disorders | 0/230 | 0/232 | 1/225 | 0/224 |
| PainGeneral disorders | 0/230 | 0/232 | 1/225 | 0/224 |
| Arthropod biteInjury, poisoning and procedural complications | 0/230 | 0/232 | 1/225 | 0/224 |
| InjuryInjury, poisoning and procedural complications | 0/230 | 0/232 | 1/225 | 0/224 |
| HemiplegiaNervous system disorders | 0/230 | 0/232 | 1/225 | 0/224 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/230 | 0/232 | 1/225 | 0/224 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/230 | 0/232 | 0/225 | 0/224 |
| Event | Placebo - Double-Blind Treatment Phase | Galcanezumab 120mg - Double-Blind Treatment Phase | Placebo/Galcanezumab 120mg - Open-Label Treatment Phase | Galcanezumab 120mg/Galcanezumab 120mg - Open-Label Treatment |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/230 | 16/232 | 11/225 | 8/224 |
| Injection site painGeneral disorders | 13/230 | 5/232 | 11/225 | 5/224 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo/Galcanezumab 120mg | Galcanezumab 120mg | Total |
|---|---|---|---|
| Mean | 45.67 ± 12.33 | 45.87 ± 11.34 | 45.77 ± 11.83 |
| Sex: Female, Male(Participants) | Placebo/Galcanezumab 120mg | Galcanezumab 120mg | Total |
|---|---|---|---|
| Female | 202 | 195 | 397 |
| Male | 28 | 37 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/Galcanezumab 120mg | Galcanezumab 120mg | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 15 | 31 |
| Not Hispanic or Latino | 174 | 172 | 346 |
| Unknown or Not Reported | 40 | 45 | 85 |
| Race (NIH/OMB)(Participants) | Placebo/Galcanezumab 120mg | Galcanezumab 120mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 35 | 37 | 72 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 5 |
| White | 182 | 183 | 365 |
| More than one race | 3 | 0 | 3 |
| Unknown or Not Reported | 7 | 8 | 15 |
| Monthly Migraine Headache Days(Days) | Placebo/Galcanezumab 120mg | Galcanezumab 120mg | Total |
|---|---|---|---|
| Mean | 13.01 ± 5.73 | 13.44 ± 6.08 | 13.23 ± 5.91 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company